Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- August 13, 2026
- Closes
- See announcement
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.866
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.866 across FY2025–FY2027, from public federal spending records.
- FY2025 obligated
- $3.9B
- FY2026 obligated
- $3.9B
- FY2027 (to date) obligated
- $0
- Awards in window
- 10,710
Top recipients: Washington University, the, Regents of the University of Michigan, University of Southern California, The Trustees of Columbia University in the City of New York, Regents of the University of California, San Francisco, the
Source: USAspending.gov · refreshed October 2026 · Program page: awards, recipients and the opportunities under this listing →
Synopsis
The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to solicit applications that propose pre-clinical and early-stage clinical (Phase I) development of novel small-molecule and biologic drug candidates that aim to prevent Alzheimer's disease (AD), slow its progression, or treat its cognitive and behavioral symptoms.
Through the NOFO, NIA is continuing the Alzheimer's Drug-Development Program (ADDP) with the aim of catalyzing drug development for AD. The ADDP is designed to provide funding support to academic and biotech researchers for preclinical drug development activities that can be conducted in their own laboratories or conducted in collaboration with contract research organizations that specialize in preclinical drug development activities. By supporting the most challenging and costly steps of drug development and seamlessly connecting preclinical drug development and first-in-human testing for drug candidates, the ADDP program seeks to:
- Continue to expand the number of investigational new drug candidates for a portfolio of emerging therapeutic targets;
- Continue to expand the therapeutic pipeline for AD with drug candidates targeting multiple underlying disease mechanisms that can be used as mono-therapy or as part of combination therapy; and
- Enable a precision medicine approach to AD drug development.
The NOFO will utilize the U01 activity code. Applications are not being solicited at this time. This notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects.
Who can apply
- State governments
- Public housing authorities/Indian housing authorities
- Native American tribal governments (Federally recognized)
- Independent school districts
- Public and State controlled institutions of higher education
- Special district governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- County governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- For profit organizations other than small businesses
- City or township governments
- Private institutions of higher education
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source — applying is free.
New to federal funding? How to read an announcement · Who can apply · How grants work
Tell me when this program posts again
One email the morning after this program opens for applications — under this number or a new one — and one more about a week before it closes (the next morning, if it is already closer than that). That is all this sends — it is not a newsletter signup.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon — the same list for everyone. Unsubscribe any time.
Similar grants
- Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
- Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)
- Translational Bioinformatics and Experimental Approaches to Advance Drug Repositioning and Combination Therapy Development for Alzheimers Disease and Related Dementias (R01 Clinical Trial Not Allowed)
- Expanding the Therapeutic Pipeline for Treating and Preventing Alzheimer's Disease and Related Dementias: Preclinical Validation and Drug Discovery for Novel Candidate Targets (U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Biomedical Research Environment and Sponsored Programs Administration Development (BRE-SPAD) Program (UC2- Clinical Trial Not Allowed)
Same-day alerts, matched to you
The free digest is weekly — the same list for everyone. Members get every open federal grant scored to their organization — and an alert the day a real match posts: we read every new posting the day it opens. Free for 30 days, then $29/mo. Card required, cancel any time before day 31.
Not ready for a subscription? A one-time Fit Report — $29 — scores every open federal grant to your organization once, by email within one business day.
See pricing